PUMA BIOTECHNOLOGY, INC. Accounts Receivable, before Allowance for Credit Loss
PUMA BIOTECHNOLOGY, INC. (PBYI) had Accounts Receivable, before Allowance for Credit Loss of $34.06 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AccountsReceivableGross · last filed 2026-08-06
- 2026-06-30: Accounts Receivable, before Allowance for Credit Loss $34.06M.
- 2026-03-31: Accounts Receivable, before Allowance for Credit Loss $26.33M.
- 2025-12-31: Accounts Receivable, before Allowance for Credit Loss $53.65M.
- 2025-09-30: Accounts Receivable, before Allowance for Credit Loss $33.56M.
| Period end | Accounts Receivable, before Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $34.06M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $26.33M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $53.65M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $33.56M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $26.12M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $25.75M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $32.37M 10-K · filed 2026-02-26 |
| 2024-09-30 | $55.40M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $28.91M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $25.57M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $48.72M 10-K · filed 2025-02-27 |
| 2023-09-30 | $29.49M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $31.29M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $31.16M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $40.35M 10-K · filed 2024-02-29 |
| 2022-09-30 | $28.03M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $33.99M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $27.04M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $32.53M 10-K · filed 2023-03-02 |
| 2021-09-30 | $23.80M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $30.55M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $27.16M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $26.54M 10-K · filed 2022-03-03 |
| 2019-12-31 | $28.90M 10-K · filed 2021-03-01 |
| 2019-09-30 | $24.68M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $25.35M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $20.98M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $20.77M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |